Viral gene evolution is a dynamic process characterized by the continuous adaptation and modification of viral genetic material over time. This phenomenon is driven by several factors, including natural selection, genetic mutations, and recombination events, resulting in the diversity of viral populations. Mutations in viral genes occur as a natural consequence of viral replication, with some mutations conferring advantages, disadvantages, or neutral effects on viral fitness. Positive selection favors mutations that enhance viral replication, transmission, or evasion of host immune responses. Recombination, where genetic material from different viruses combines, further contributes to viral gene evolution. This process can lead to the emergence of novel viral strains with unique genetic compositions and potentially altered biological properties. Selective pressures, such as host immune responses and antiviral interventions, play a crucial role in shaping viral gene evolution. Rapid evolution allows viruses to evade immune recognition and develop resistance to antiviral drugs. Understanding viral gene evolution is essential for designing effective vaccines and antiviral strategies. Ongoing research explores the molecular mechanisms driving viral evolution, aiding in the prediction of emerging viral threats and the development of targeted interventions to mitigate their impact.
Title : A promising novel approach to DNA vaccines
Khursheed Anwer, IMUNON, United States
Title : Prophylactic and molecular approaches for mitigating human influenza A viruses: i. Evaluating influenza vaccine effectiveness in the older population ii. Down-regulation of influenza virus genes with novel sirna-chimeric-ribozyme constructs
Madhu Khanna, University of Delhi, India
Title : The importance of post-marketing surveillance and real-world data: For a product to be successful
Regina Au, BioMarketing Insight, United States
Title : Development of a novel multi-component vaccine to address the burden of otitis media in high-risk populations
Ayesha Zahid, Griffith University, Australia
Title : New biomarkers in leishmania major vaccine development
Negar Seyed, Pasteur Institute of Iran, Iran (Islamic Republic of)
Title : Approaches towards developing and establishing a biomanufacturing research & development, and manufacturing industry in Zimbabwe: A review of the need, potential funding sources, policy development and implementation
Elliot Nyagumbo, Midlands State University, Zimbabwe
Title : Evaluating the immunogenic impact of process impurities in mRNA vaccine production: Establishing integrated control strategies and specifications
Jesse Kuiper, Merck Research Laboratories, United States
Title : Capillary electrophoresis for adjuvanted multivalent recombinant vaccine purity determination
Ashley Prout, Merck, United States
Title : Hypersensitivity and anti-SARS-COV-2 vaccination: A retrospective study of the year 2021 at the University Hospital Center of Tours (France)
Faure Quentin, The Savoie Metropolitan Hospital Center, France
Title : THE HPV vaccination program in Colombia. From a beautiful dream to a nightmare, but hopefully with a bright dawn.
Carlos Castro, Colombian League against cancer, Colombia